Core Insights - The Hong Kong stock market has seen a significant increase in IPO activity, with 17 companies listed in Q1 2024, raising a total of 18.7 billion HKD, nearly four times the amount from the same period in 2023 [2] - The Hong Kong Stock Exchange (HKEX) is enhancing its appeal to mainland companies through systematic institutional innovations and process optimizations, including the introduction of a "special line" for technology companies [2][4] - A seminar titled "潮起香江 聚势共赢" will be held in May 2025 to discuss the integration of Shenzhen and Hong Kong capital markets and the opportunities for mainland companies to leverage the Hong Kong market for international expansion [1][3] Group 1: Market Trends - The HKEX continues to attract mainland enterprises, with 130 companies currently in the listing application process as of April 30, 2024 [2] - Notable upcoming listings include CATL, which plans to issue 118 million shares to raise approximately 30.7 billion HKD [2] - The seminar aims to address how Shenzhen technology companies can utilize both markets and resources for global development [3] Group 2: Challenges and Opportunities - A survey conducted prior to the seminar identified key challenges faced by mainland companies in the IPO process, including unfamiliarity with Hong Kong's listing rules, high costs, and differences in accounting standards [4][5] - Companies expressed a desire for support in understanding listing policies, sharing experiences, and connecting with Hong Kong capital market resources [5] - The seminar will provide a platform for expert insights and direct consultations with HKEX representatives to address these challenges [6][7] Group 3: Seminar Structure - The seminar will feature a comprehensive agenda, including expert interpretations of market trends and policies, interactive Q&A sessions, and one-on-one consultations with HKEX officials [6] - Successful companies like SF Express and Jingtai Technology will share their experiences in navigating the IPO process [6] - Participants will also have the opportunity to visit the Hong Kong financial market and engage with key financial institutions [6]

Core Viewpoint - The chairman and general manager of Maiwei Biotech, Liu Datao, has been placed under investigation by the China Securities Regulatory Commission (CSRC) for suspected short-term trading, which raises concerns about the company's governance and its upcoming IPO in Hong Kong [1][5][6]. Company Overview - Maiwei Biotech is an innovative pharmaceutical company that has not yet achieved profitability, despite having three products on the market. The company has reported significant cumulative losses due to high research and development costs [4][5]. - As of the end of Q1 2023, Liu Datao held 15.1 million shares, representing 3.78% of the total share capital, making him the third-largest shareholder [3]. Financial Performance - The company reported revenues of approximately 44.79 million yuan in Q1 2023, a year-on-year decline of 33.7%. The corresponding net loss was about 292 million yuan, indicating an increase in losses compared to the previous year [5]. - Financial data for 2022-2024 shows revenues of approximately 27.73 million yuan, 128 million yuan, and 200 million yuan, with net losses of approximately 955 million yuan, 1.053 billion yuan, and 1.044 billion yuan respectively [3][4]. IPO Plans - Maiwei Biotech is planning to issue shares (H-shares) and list on the Hong Kong Stock Exchange to meet its funding needs for sustainable development and enhance its international profile. The company submitted its IPO application earlier this year [5]. - The investigation of the chairman may impact the IPO process, as regulatory bodies may extend the inquiry period and require additional information regarding the company's governance and internal controls [6].

Group 1: Core Insights - The surge in enthusiasm for mainland companies to list in Hong Kong is driven by favorable policy environments, efficient listing measures from the Hong Kong Stock Exchange (HKEX), strong market performance, and the internal development needs of companies [1][10]. Group 2: Policy Environment - A series of measures have been implemented to create a friendly policy environment for mainland companies seeking overseas listings, including simplified foreign exchange registration procedures and enhanced funding management [1]. - The regulatory framework has been upgraded to provide robust institutional support for mainland companies, ensuring a transparent and efficient regulatory environment [1]. Group 3: HKEX Listing Measures - HKEX has introduced systematic innovations and process optimizations to enhance its competitiveness in the international capital market, including the launch of a "Special Line for Technology Companies" to facilitate financing for tech firms [3]. - Reforms in listing rules and market structure are underway to streamline the listing approval process and improve efficiency [3][4]. Group 4: Market Performance - The Hong Kong market has outperformed others, with a total of HKD 112.50 billion raised through IPOs in 2025, compared to approximately RMB 89.626 billion in A-shares and USD 1.95 billion in US-listed Chinese companies [6][7]. - The Hang Seng Index has risen by 14.37% and the Hang Seng Tech Index by 23.89% in 2025, showcasing the strong vitality of the Hong Kong market [7]. Group 5: Company Development Needs - The ongoing adjustments in global trade dynamics and US tariff policies have led many Chinese companies to accelerate overseas investment, with Hong Kong and US markets serving as strategic platforms for foreign currency funding and global brand building [9]. - Some mainland companies view listing in Hong Kong as a critical pathway to overcome funding bottlenecks and achieve business expansion, as exemplified by the restaurant chain Lao Xiang Ji [9]. - Listing in Hong Kong not only serves as a financing option but also as an opportunity for companies to enhance governance and operational efficiency by integrating with international capital markets [9].

中国企业 赴港上市热情持续高涨，深圳科创企业如何借力香港国际资本市场实现战略跃升？如何把握港 交所政策新规的时代机遇？ 2025年5月15日-5月16日，诚邀您共赴"潮起香江 聚势共赢——深港资本市场融 合发展与赴港上市专题研讨会" ，探索帮助深圳企业利用好境内外两个市场、两种资源实现高质量发展，融 入全球化发展。 一、活动背景 为深入贯彻落实党的二十届三中全会、中央经济工作会议精神，更好服务科技创新和民营经济高质量发 展，不断深化深港双城联动，促进深港协同发展，支持香港巩固提升国际金融中心地位，促进深圳科技企业 利用好两个市场、两种资源实现规范健康发展，通过境外上市融资开拓国际市场，融入全球化发展，建设高 水平开放型经济新发展格局，在中共深圳市委金融委员会办公室、深圳市中小企业服务局的指导下，福田区 政府、河套深港科技创新合作区深圳园区发展署特别支持下，证券时报社联合香港公司治理公会，深圳市金 融稳定发展研究院举办 "潮起香江 聚势共赢——深港资本市场融合发展与赴港上市专题研讨会" ，邀请相关 嘉宾与专家介绍香港上市的相关情况、解读政策新规，组织参访港交所与国际金融机构。 二、组织单位 9:20--9:50 ...

内地企业赴港上市热情持续高涨，深圳科创企业如何借力香港国际资本市场实现战略跃升？如何把握港交所政策新规的时代机遇？2025年5月15日—5月16 日，诚邀您共赴"潮起香江 聚势共赢——深港资本市场融合发展与赴港上市专题研讨会"，探索帮助深圳企业利用好境内外两个市场、两种资源实现高质 量发展，融入全球化发展。 一、活动背景 为深入贯彻落实党的二十届三中全会、中央经济工作会议精神，更好服务科技创新和民营经济高质量发展，不断深化深港双城联动，促进深港协同发展， 支持香港巩固提升国际金融中心地位，促进深圳科技企业利用好两个市场、两种资源实现规范健康发展，通过境外上市融资开拓国际市场，融入全球化发 展，建设高水平开放型经济新发展格局，在中共深圳市委金融委员会办公室、深圳市中小企业服务局的指导下，福田区政府、河套深港科技创新合作区深 圳园区发展署特别支持下，证券时报社联合香港公司治理公会，深圳市金融稳定发展研究院举办"潮起香江 聚势共赢——深港资本市场融合发展与赴港上 市专题研讨会"，邀请相关嘉宾与专家介绍香港上市的相关情况、解读政策新规，组织参访港交所与国际金融机构。 二、组织单位 2025年5月16日9:00-17: ...

那么，对于企业和各类中介机构而言，当前赴港上市有哪些新变化、新规定、新要求？在具体实务过程 中又有哪些需要我们注意的要点？ 我们在此做了简单的梳理，以期帮助大家快速掌握 目前香港上市的制度与业务流程、发行架构、上市 模式，以及法律和财税等实务要 点： └ 香港政府对于证券市场的支持 香港交易及结算所有限公司 (港交所) 香港资本市场的 香港联合交易所有限公司 (香港联交所) 监管主体及职责 香港证券及期货事务监察委员会 (香港证监会) -主板 (Main Board) 上市板块选择- -GEM (Growth Enterprise Market) 上市规则框架和财务要求 - 特专科技公司的行业名单和上市条件 不同赴港主板上市情形下有关上市资格的规则适用 营业记录及财务资格 管理层延续性 香港联交所 拥有权和控制权延续性 上市板块及上市条件 业务经营可持续性 主板上市规则下的 上市资格及上市合适性 对第三方的重大依赖 对公司有重大影响人士 及董事的合适性 不合规事件 -与控股股东的竞争 盈利测试 香港联交所主板 境外篇 市值/收入测试 上市财务要求 市值/收入/现金流测试 - VIE架构的界定 合理性论证&最低 ...